Related Experiment Videos
Gliclazide: metabolic and vascular effects--a perspective
K G Alberti1, A B Johnson, R Taylor
1Human Diabetes and Metabolic Research Centre, University of Newcastle upon Tyne, England.
Metabolism: Clinical and Experimental
|May 1, 1992
Summary
Gliclazide effectively manages non-insulin-dependent diabetes mellitus (NIDDM) by improving metabolic control and offering unique nonmetabolic benefits. This sulfonylurea lowers blood glucose and lipids, potentially preventing diabetic complications.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Gliclazide, a second-generation sulfonylurea, is a common treatment for non-insulin-dependent diabetes mellitus (NIDDM).
- Its use is supported by both metabolic and nonmetabolic effects, impacting glycemic control and potentially reducing diabetes-related complications.
Purpose of the Study:
- To evaluate the metabolic and nonmetabolic effects of gliclazide in NIDDM patients.
- To assess its efficacy in improving glycemic control and its potential role in preventing diabetic micro- and macroangiopathy.
Main Methods:
- The study reviews existing literature on gliclazide's mechanisms of action and clinical outcomes.
- Analysis focuses on its impact on insulin secretion, insulin resistance, lipid levels, platelet function, endothelial function, and free radical status.
Main Results:
- Gliclazide demonstrates significant benefits in metabolic control, lowering blood glucose and lipid levels.
- Glucose reduction is attributed to enhanced insulin secretion (via K+ ATP channel closure) and decreased insulin resistance.
- Nonmetabolic effects include improved platelet behavior, endothelial function, and antioxidant status, potentially aiding in the prevention of diabetic complications.
Conclusions:
- Gliclazide offers significant metabolic advantages for NIDDM management, improving glycemic and lipid control.
- Unique nonmetabolic effects suggest a role in preventing diabetic micro- and macroangiopathy.
- Gliclazide is a suitable treatment option for NIDDM patients unresponsive to diet alone, considering both its metabolic and nonmetabolic properties.